Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Non-Current Deffered Revenue (2016 - 2020)

Agios Pharmaceuticals (AGIO) has disclosed Non-Current Deffered Revenue for 9 consecutive years, with $491000.0 as the latest value for Q2 2020.

  • For Q2 2020, Non-Current Deffered Revenue changed N/A year-over-year to $491000.0; the TTM value through Jun 2020 reached $491000.0, changed N/A, while the annual FY2019 figure was $50.6 million, 15.43% down from the prior year.
  • Non-Current Deffered Revenue hit $491000.0 in Q2 2020 for Agios Pharmaceuticals, down from $50.6 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $154.3 million in Q4 2016 and bottomed at $491000.0 in Q2 2020.
  • Average Non-Current Deffered Revenue over 5 years is $59.7 million, with a median of $52.8 million recorded in 2019.
  • On a YoY basis, Non-Current Deffered Revenue climbed as much as 7626.83% in 2017 and fell as far as 88.23% in 2017.
  • Agios Pharmaceuticals' Non-Current Deffered Revenue stood at $154.3 million in 2016, then tumbled by 88.23% to $18.2 million in 2017, then soared by 229.44% to $59.8 million in 2018, then decreased by 15.43% to $50.6 million in 2019, then plummeted by 99.03% to $491000.0 in 2020.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $491000.0, $50.6 million, and $49.8 million for Q2 2020, Q4 2019, and Q3 2019 respectively.